Vimarsana
Biggest News Aggregation in the World

Page 16 - Preliminary Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Preliminary Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Preliminary Data Today - Breaking & Trending Today

RTCG - Radio Televizija Crne Gore - Nacionalni javni servis :: Svijet :: Rekordno krčenje šuma u brazilskoj Amazoniji - Vimarsana News

RTCG - Radio Televizija Crne Gore - Nacionalni javni servis :: Svijet :: Rekordno krčenje šuma u brazilskoj Amazoniji

Preliminarni državni podaci izazvali su zabrinutost da će predstojeća sušna sezona donijeti još više krčenja šuma u brazilskom dijelu Amazonije od prošlogodišnjeg naleta sječe.

Source: rtcg.me
The Pandemic Suicide Crisis Is Unsupported by the Data - Vimarsana News

The Pandemic Suicide Crisis Is Unsupported by the Data

The Atlantic The Suicide Wave That Never Was The notion that lockdowns increased the rate of death by suicide last year has become common knowledge. It’s not backed up by data. In January, The New York Times published an alarming article about teen suicides during the pandemic. The story featured heartbreaking quotes from parents who had lost children, and was illustrated with photos of an empty classroom and a teenager sitting alone on his bed. The school district of Clark County, Nevada, the story said, had recorded the deaths of 18 students from suicide from mid-March 2020 to the end of...

Anokion SA: Anokion Announces Initiation of Multiple-Ascending Dose Portion of its Phase 1 Clinical Trial with KAN-101 for the Treatment of Celiac Disease - Vimarsana News

Anokion SA: Anokion Announces Initiation of Multiple-Ascending Dose Portion of its Phase 1 Clinical Trial with KAN-101 for the Treatment of Celiac Disease

(0) Preliminary Data from Single-Ascending Dose Cohorts Expected Later this Year Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that the company has initiated patient dosing in the multiple ascending dose (MAD) portion of its ACeD study (Assessment of KAN-101 in Celiac Disease), a Phase 1 clinical trial evaluating KAN-101 for the treatment of individuals with celiac disease. Initiation of the MAD cohort enrollment follows completion of the first two single-ascending dose (SAD) cohorts in the trial, wit...

Exports rise 17.3% to $14 bn in first 2 weeks of March - Vimarsana News

Exports rise 17.3% to $14 bn in first 2 weeks of March

Showing healthy signs of revival, India’s exports grew 17.3% to $14.22 billion during March 1-14 compared with a year earlier, according to the Commerce Ministry’s preliminary data.Imports during the

Bireme Capital: "Vaxart, Inc. is Exhibiting Classic Pretender Signals" - Vimarsana News

Bireme Capital: "Vaxart, Inc. is Exhibiting Classic Pretender Signals"

Bireme Capital: “Vaxart, Inc. (VXRT) is Exhibiting Classic Pretender Signals” Bireme Capital, an investment management firm, published its fourth-quarter 2020 Investor Letter – a copy of which can be downloaded here. A net return of 47.1% was recorded by the fund for the year end 2020, outperforming its S&P500 benchmark that delivered an 18.3% return. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021. Bireme Capital, in their Q4 2020 investor letter, said that they find it nearly inconceivable that Vaxart, Inc. (NASDAQ: VXRT) will develop a commerciall...